KALA BIO, Inc. (KALA) Fair Value 2026

KALA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.7 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-28, KALA BIO, Inc. (KALA) trades at $0.69, versus a $0.24 median fair value across its 2 active models — 65.7% below the current price. QOC: 3.7/10. Value Trap Risk: 42/100 (WARN). 2/13 models active.

Key Facts

Ticker
KALA
Price
$0.69
Quality Score
3.7/10
Value Trap Risk
42/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

Is KALA BIO, Inc. (KALA) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, KALA BIO, Inc. (KALA) appears overvalued as of : the median of 2 independent fair value estimates is $0.24, 65.7% below the current price of $0.69. Estimates range from $0.19 to $0.28. KALA scores 3.7/10 on fundamental quality and 42/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. KALA’s -65.7% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy KALA BIO, Inc. Stock in 2026? →

What Fair Value Does Each Model Give KALA?

2 Intrinsic Value Models vs. Current Price ($0.69)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.28 -59.6%
Option-Based · Medium Conviction
 $0.19 -71.9%

All Models Active

All 2 models are displayed above.

What Is KALA BIO, Inc. (KALA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, KALA BIO, Inc.'s intrinsic value is estimated at $0.24, suggesting the stock is overvalued at its current price of $0.69. With 2 out of 2 models flagging downside (-65.7% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About KALA?

2 of 13 models are currently active for KALA. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for KALA is $0.24 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does KALA Rank in Biotechnology?

Among 625 Biotechnology stocks, KALA ranks #563 by Quality of Company score. CirclFi's QOC score of 3.7/10 evaluates 32 fundamental signals. A score of 3.7 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, KALA BIO, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating KALA should weigh these sector-specific dynamics alongside our model-derived fair values.

Is KALA a Value Trap?

CirclFi's Value Trap algorithm assigns KALA a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for KALA BIO, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, KALA BIO, Inc.'s fundamental quality profile registers 3.7/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

Models cluster within a tight range (+12.3% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every KALA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across KALA's 2 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy KALA BIO, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

PBLSParabilis Medicines, Inc.QOC 3.7RNAAtrium Therapeutics, Inc.QOC 3.7BIVIBioVie Inc.QOC 3.7ALZNAlzamend Neuro, Inc.QOC 3.7SKYESkye Bioscience, Inc.QOC 3.7HEPAHepion Pharmaceuticals, Inc.QOC 3.6DYAIDyadic International, Inc.QOC 6.5PLURPluri Inc.QOC 5.3VIVSVivoSim Labs, Inc.QOC 4.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: PBLS · RNA · BIVI · ALZN · SKYE · HEPA · DYAI · PLUR · VIVS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to KALA?

5 companies across all industries closest to KALA’s Quality of Company score of 3.7/10.

LBSRLiberty Star Uranium & Metals Corp.QOC 3.7BRBIBRBI BR Partners S.A.QOC 3.7ODYYOdyssey Health, Inc.QOC 3.7SDOTSadot Group Inc.QOC 3.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LBSR · BRBI · ODYY · SDOT · NVDA

Where Does KALA Sit in CirclFi's Biotechnology Rankings?

KALA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About KALA BIO, Inc.’s Valuation?

What is KALA BIO, Inc.'s intrinsic value in 2026?

CirclFi puts KALA BIO, Inc. (KALA)'s intrinsic value at $0.24 — the median of 2 independent model estimates as of 2026-08-28, ranging from $0.19 to $0.28. The Quality of Company score is 3.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is KALA overvalued or undervalued right now?

At $0.69, 0 of 2 active models suggest KALA may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $0.24, 65.7% below the current price of $0.69 — a consensus view that KALA is overvalued. The assessment depends on which methodology best fits KALA BIO, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.7 mean for KALA?

KALA BIO, Inc.'s QOC of 3.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on KALA?

CirclFi analyzes KALA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is KALA a value trap in 2026?

KALA BIO, Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, KALA BIO, Inc. (KALA) has a median fair value of $0.24 — 65.7% below the current price of $0.69 — as of 2026-08-28.” Source: circlfi.com/stock/KALA/ · Methodology
Primary sources for this KALA valuation
  • Financial statements: KALA BIO, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001479419) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for KALA as of ; valuations recomputed .